‘SKINNY JABS': WEIGHT-LOSS DRUGS SET FOR NEW BOOM AS GENERIC VERSIONS EMERGE

Summary from the TLDR newsletter

Generic versions of Wegovy, Saxenda, Ozempic, and Victoza are set to hit the market soon at a lower cost than the original drugs. Patents for liraglutide, which is in Victoza and Saxenda, have expired. Teva Pharmaceutical Industries, the world's largest generic drugmaker, has already launched a generic version of Victoza in the US. Pfizer, Viatris' Mylan, and Novartis' Sandoz are also planning to launch their own generic liraglutide products. Ozempic and Wegovy will lose patent protection in China in 2026, in Europe and Japan in 2031, and in the US in 2032.